All In Biotech

Drug Trial Radar · NCT04718844

A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

A Randomised, Single-blind, Placebo-controlled, Phase 1, Single-ascending and Multiple-dose Study in Adult Subjects With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome to Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124.

Last checked: Nov 19, 2026Latest source record: Jan 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

44

Actual

Start

Apr 14, 2021

Primary completion

May 23, 2023

Study completion May 23, 2023

Sponsor

Lead sponsor
Silence Therapeutics plcIndustry
Sponsor type
Industry
First posted
Jan 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate the safety and tolerability of SLN124 in patients with Thalassaemia or patients with Very Low- and Low-risk Myelodysplastic Syndrome (MDS) after single ascending s.c. doses and multiple doses in healthy male and female subjects. Up to 7 cohorts of 56 patients with Thalassaemia and up to 7 cohorts of 56 patients with MDS will be enrolled. Each subject will receive single or multiple doses of SLN124 or placebo given by subcutaneous (s.c) injection.

Conditions

  • Non-transfusion-dependent Thalassemia
  • Low Risk Myelodysplastic Syndrome
  • Very-Low Risk Myelodysplastic Syndrome

Interventions

  • SLN124Drug

    SLN124 for subcutaneous (s.c.) injection

  • PlaceboDrug

    Sodium chloride for s.c. injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse eventsTime frame: Day 84
  2. Incidence of treatment-emergent adverse eventsTime frame: Day 140

Locations

20 sites in 7 countries. Site status is shown where the registry gives one.

  • Universitaetsklinikum Duesseldorf

    Düsseldorf, Germany

  • Universitat Leipzig

    Leipzig, Germany

  • Rambam Health Care Campus

    Haifa, Israel

  • Sheba Medical Center

    Ramat Gan, Israel

  • Bar-Ilan University - Faculty of Medicine

    Safed, Israel

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • AUSL della Romagna - Ospedale di Ravenna

    Ravenna, Italy

  • Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia

    Reggio Emilia, Italy

  • Jordan University Hospital

    Amman, Jordan

  • King Hussein Cancer Center

    Amman, Jordan

  • Irbid Speciality Hospital

    Irbid, Jordan

  • Sarawak General Hospital

    Kampung Sarawak, Malaysia

  • Hospital Ampang

    Kampung Selangor, Malaysia

  • King Chulalongkorn Memorial Hospital

    Bangkok, Thailand

  • Mahidol University - Faculty of Medicine - Ramathibodi Hospital

    Bangkok, Thailand

  • Mahidol University - Siriraj Hospital

    Bangkok, Thailand

  • Faculty of Medicine, Chiang Mai University

    Chiang Mai, Thailand

  • University Hospital of Wales

    Cardiff, United Kingdom

  • The Leeds Teaching Hospitals NHS Trust - Saint James's University Hospital

    Leeds, United Kingdom

  • Hammersmith Medicines Research Ltd (HMR)

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.